Our group, as well as others, including large cooperative studies reported by the Gynecologic Oncology Group, has previously shown that up to 50% of USPC patients may overexpress HER2/neu in their tumour, and these tumours may be more biologically aggressive than cancers that do not overexpress the receptor (Santin et al, 2002; Slomovitz et al, 2004; Santin et al, 2005a, 2005b; Diaz-Montes et al, 2006; Villella et al, 2006; Grushko et al, 2008). The gene discussed is ERBB2; the disease is cancer.